Share on Pinterest Michelle (pictured left) and her daughter Samantha Pearson live with NF1-PN, a chronic disease in which tumors grow along nerves. Photography courtesy of Michelle Pearson A ...

SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology drug Dupixent as a therapy for rare skin disease prurigo nodularis (PN).

EMA committee recommends marketing approval for SpringWorks’ mirdametinib to treat adult & paediatric patients with NF1-PN: Stamford, Connecticut Tuesday, May 27, 2025, 12:00 Hr ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Last week Frank Esposito shared his forecast for summer resin prices for PE, PP, PS and PVC as tumultuous conditions are keeping prices flat or down. Watch a clip of it in Material Insights. From the ...

Residential houses are seen destroyed after a Russian drone strike in Pryluky village, Ukraine, Thursday, June 5, 2025.

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Many people today are suffering from toes/feet or fingers/hands that burn, tingle, feel numb and yet painful at the same time ...

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

Mirdametinib is approved in the U.S. for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) ...

Evidence of Disease Modification on Clinical and Biomarker Measures: Favorable trends indicating stability or improvement were observed in patients with ATTRv-PN, including six patients previously ...